All In Biotech

Drug Trial Radar · NCT04234204

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Mar 17, 2020

Primary completion

Apr 20, 2022

Study completion Apr 20, 2022

Sponsor

Lead sponsor
Astellas Pharma China, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jan 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments are fezolinetant (1 tablet) once a day or placebo (1 tablet) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study will compare fezolinetant and placebo after 4 and 12 weeks of dosing. The study will see if fezolinetant reduces the number of hot flashes. And the study will see if fezolinetant reduces the severity of the hot flashes. Women in the study will receive an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants will use this to record their hot flashes. Their record for the 10 days before the start of study treatment will be checked. They can remain in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they will be picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin. The study participants will take study treatment for 24 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors do not know who takes which of the study treatments (fezolinetant or placebo) during that time. The last 12 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors know which study treatment that study participant takes during that time. Women who take fezolinetant during the first 12 weeks will continue to take fezolinetant. Women who take placebo during the first 12 weeks will start taking fezolinetant. At weeks 2, 4, 8, 12, 14, 16, 20 and 24, the study participants will go to the hospital or clinic for a check-up. They will be asked about medications, side effects and how they feel. Other checks will include physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be collected for laboratory tests. Study participants will complete questionnaires that are about how hot flashes affect their daily life. Study participants who still have their uterus will have the following 2 tests done at the first and last study visits if they meet the criteria. One of the 2 tests is endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue is then checked under a microscope. The other test is transvaginal ultrasound. This test uses sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which is placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months will have it done at the first study visit. They will have it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic will be 3 weeks after the last dose of study treatment.

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    Oral

  • PlaceboDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS)Time frame: Baseline to Week 4
  2. Mean change from baseline in the frequency of moderate to severe VMSTime frame: Baseline to Week 12
  3. Mean change from baseline in the severity of moderate to severe VMSTime frame: Baseline to Week 4
  4. Mean change from baseline in the severity of moderate to severe VMSTime frame: Baseline to Week 12

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • Site CN86001

    Beijing, China

  • Site CN86002

    Beijing, China

  • Site CN86017

    Beijing, China

  • Site CN86030

    Beijing, China

  • Site CN86022

    Changchun, China

  • Site CN86009

    Changsha, China

  • Site CN86037

    Chengdu, China

  • Site CN86006

    Guangzhou, China

  • Site CN86019

    Guangzhou, China

  • Site CN86042

    Guangzhou, China

  • Site CN86043

    Guangzhou, China

  • Site CN86018

    Guiyang, China

  • Site CN86025

    Hangzhou, China

  • Site CN86034

    Hangzhou, China

  • Site CN86027

    Kunming, China

  • Site CN86005

    Liuzhou, China

  • Site CN86004

    Nanjing, China

  • Site CN86011

    Nanjing, China

  • Site CN86035

    Nanjing, China

  • Site CN86026

    Nanning, China

  • Site CN86012

    Shanghai, China

  • Site CN86021

    Shenzhen, China

  • Site CN86007

    Shijiazhuang, China

  • Site CN86023

    Taiyuan, China

  • Site CN86031

    Taiyuan, China

  • Site CN86015

    Tianjin, China

  • Site CN86029

    Tianjin, China

  • Site CN86008

    Wuhan, China

  • Site CN86041

    Yangzhou, China

  • Site CN86013

    Yinchuan, China

  • Site CN86033

    Zhongshan, China

  • Site KR82013

    Ansan-si, South Korea

  • Site KR82005

    Busan, South Korea

  • Site KR82003

    Seongnam-si, South Korea

  • Site KR82011

    Seongnam-si, South Korea

  • Site KR82001

    Seoul, South Korea

  • Site KR82002

    Seoul, South Korea

  • Site KR82004

    Seoul, South Korea

  • Site KR82006

    Seoul, South Korea

  • Site KR82012

    Seoul, South Korea

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.